News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Key Points Interested in Rigetti Computing, Inc.? Here are five stocks we like better. Revenue increased sharply: Rigetti reported Q2 2026 revenue of approximately $5.1 million, up from $1.8 million a year earlier, driven by Novera quantum processing unit sales. Gross margin also improved …
Sharemaestro market context Price above Trend Line 52 weeks +16.5%Rigetti Computing (RGTI) reported a wider non-GAAP loss of $0.05 per diluted share in Q2, compared to a loss of $0.04 per share in the previous year. However, the company's revenue increased to $3.4 million from $2.1 million year-over-year. The article mentions that further …
Rigetti Computing announced its second-quarter 2026 financial results, reporting $5.1 million in total revenues and a GAAP net loss of $52.6 million. The company highlighted strategic advancements including an expanded collaboration with Hewlett Packard Enterprise and the Pittsburgh Supercomputing Center for a hybrid quantum-classical …
Sharemaestro market context Price above Trend Line 52 weeks +16.5%The article discusses how Precigen, Inc. exceeded expectations, leading analysts to update their financial estimates for the company. This suggests a positive outlook for Precigen's future performance based on recent results.
Prestige Consumer Healthcare reported strong Q1 fiscal 2027 results with revenue up 6.5% to $265.7 million and adjusted diluted EPS rising to $0.98. The company's recent acquisitions of Breathe Right and LaCorium Health significantly contributed to these results and led to a raised fiscal …
BeOne Medicines (ONC) saw its stock climb after reporting strong Q2 2026 earnings, with profits significantly increasing. While the company is showing clear profitability, its reliance on the drug BRUKINSA for the majority of its revenue raises concentration concerns among investors. The company's pipeline …
Precigen (PGEN) reported a significant return to profitability in Q2 2026, driven by strong revenue and net income largely attributed to the rapid uptake of Papsimios. The company's profitability and broad payer coverage, along with seven-year FDA market exclusivity for Papsimios, strengthen its investment …
Rigetti Computing (NASDAQ:RGTI) reported Q2 results with revenue slightly missing analyst estimates at $5.1 million versus $5.3 million expected, while non-GAAP EPS was in line at -$0.05. The stock dipped about 3.8% in after-hours trading, giving back some of its recent gains. The company …
Rigetti Computing, Inc. (RGTI) reported a Q2 loss of $0.05 per share, matching the previous year's loss, but missing the Zacks Consensus Estimate. However, the company surpassed revenue estimates, posting $5.14 million against an estimated $4.92 million. Despite recent revenue beats, RGTI shares have …
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. BeOne Medicines (ONC) is back in focus after reporting second quarter 2026 results on 5 August, with revenue and earnings surpassing analyst expectations and the …
Versigent (VGNT) stock, despite a 1.7% slip after Q2 earnings, appears cheap with a P/E near 6x and a DCF fair value estimated at US$114.51 against its current US$45 price. The company reported strong margin expansion, with adjusted EBITDA margin increasing to 11.1%, turning …
Prestige Consumer Healthcare Inc. reported a Q2 2026 revenue increase to $265.71M, up 6.5% year-over-year, driven by growth in both North America and International markets. Despite revenue growth, net income and diluted EPS declined by 38.5% and 35.8% respectively compared to the prior-year quarter. …
Rigetti Computing reported slightly better-than-expected revenue in its second quarter, driven by increasing sales of its quantum system. Despite this revenue growth, the company's stock declined due to widening losses and ongoing commercialization expenses. The article highlights that while system sales are accelerating, profitability …
Rigetti Computing, Inc. (RGTI) reported a Q2 adjusted loss of $0.05 per share, matching FactSet estimates. The company's Q2 revenue was $5.1 million, also in line with FactSet's estimate. This earnings flash indicates that Rigetti's financial performance for the second quarter was consistent with …
The article highlights three healthcare stocks—Krystal Biotech (KRYS), BeOne Medicines (ONC), and Zevra Therapeutics (ZVRA)—that retail investors are watching due to resilient hiring and growth in the healthcare sector despite a general slowdown in private sector job creation. It provides an overview of each …
Prestige Consumer Healthcare Inc. (NYSE: PBH) reported its Q1 2027 earnings, revealing a 6.5% increase in total revenues to $265.7 million for the quarter ended June 30, 2026, primarily driven by the $1,045.0 million acquisition of the OTC Wellness Business, including the Breathe Right …
Prestige Consumer Healthcare reported stronger-than-expected Q1 fiscal 2027 results, with adjusted EPS of $0.98 and revenue of $265.7 million, both exceeding analyst estimates. The company saw organic revenue growth of 3.2% and a record adjusted free cash flow of $83.7 million, while integrating the …
Rigetti Computing (NASDAQ:RGTI) saw its hardware revenue climb by 185% to $5.14 million in Q2, primarily driven by quantum system sales, which accounted for 79.8% of total revenue. However, 80% of this hardware revenue came from just two customers, and operating losses increased by …
Precigen, Inc. has filed a Form 144 notice for the sale of 32,739 common shares with an aggregate value of $224,589.54 through Fidelity Brokerage Services LLC on NASDAQ. These shares were originally acquired through restricted stock vesting as compensation on three different dates between …
Prestige Consumer Healthcare Inc. (PBH) has released its Q1 2027 earnings call presentation. The company reported an EPS of $0.98, beating estimates by $0.10, and revenue of $265.71M, surpassing expectations by $15.39M, representing a 6.48% year-over-year increase. This article provides access to the slide …
Prestige Consumer Healthcare (PBH) reported $265.71 million in revenue for the quarter ended June 2026, representing a year-over-year increase of 6.5%. EPS of $0.98 for the same period compares to $0.95 a year ago. The reported revenue compares to the Zacks Consensus Estimate of …
Conestoga Capital Advisors, an asset management company, reported a positive shift towards Small Caps in its Q2 2026 investor letter. Despite a strong market for the Russell 2000 Growth Index, Conestoga's quality-focused strategies were impacted by uneven leadership, mirroring the Tech Bubble. The firm …
Prestige Consumer Healthcare (NYSE: PBH) director Dawn M. Zier was granted 2,981 restricted stock units (RSUs) as part of the company's director compensation program. The RSUs, valued at $155,000 based on a $52.00 closing stock price, will vest on the first anniversary of the …
Prestige Consumer Healthcare Inc. (PBH) reported its Q1 revenue of $265.7 million, surpassing FactSet's estimate of $250.3 million. This positive earnings flash was published on August 6, 2026, and also follows an earlier report of the company raising its earnings guidance for fiscal year …
Prestige Consumer Healthcare Inc. reported strong first-quarter fiscal 2027 results, exceeding sales and earnings expectations with a revenue of $265.7 million, up 6.5%, and organic sales growth of 3.2%. The company closed the Breathe Right® and LaCorium acquisitions, which contributed to its performance and …
This article analyzes Rigetti Computing Inc. (NASDAQ: RGTI) using AI models, identifying strong near and mid-term sentiment but a weak long-term outlook. It highlights support testing, potential resistance, and an exceptional risk-reward setup targeting a significant gain with minimal risk. Three distinct trading strategies …
Morgan Stanley has reiterated its "Buy" rating on VERSIGENT PLC (VGNT.US) and increased its target price for the company's shares to $58. This indicates a continued positive outlook from the investment bank regarding VERSIGENT's future performance.
Versigent PLC (VGNT) has seen its average 12-month price target increase to $55.9 from $55.2, with individual forecasts ranging from $52 to $60. This new target suggests a 22% potential upside based on the Aug. 4 closing price. The stock maintains a "Buy" consensus …
H.C. Wainwright has reiterated its Buy rating for Rigel Pharmaceuticals (RIGL.US), maintaining a target price of $57. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.
Rigel Pharmaceuticals (RIGL) saw its stock rally after its Q2 earnings release, with a 4.6% increase following a strong three-month run. The company maintained profitability with $17.3m in net income and $78.7m in total revenue, though revenue and EPS declined significantly year-over-year. While the …
Search by ticker symbol or company name and select a result to open its chart.